173 related articles for article (PubMed ID: 33582956)
1. Treatment and outcomes of heparin-induced thrombocytopenia (HIT) in patients with neoplasm, a case series.
Lai CMB; Smith T; Lee AYY
J Thromb Thrombolysis; 2021 Apr; 51(3):725-733. PubMed ID: 33582956
[TBL] [Abstract][Full Text] [Related]
2. Heparin-induced thrombocytopenia from venous thromboembolism treatment.
Begelman SM; Hursting MJ; Aghababian RV; McCollum D
J Intern Med; 2005 Dec; 258(6):563-72. PubMed ID: 16313480
[TBL] [Abstract][Full Text] [Related]
3. Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia.
Al-Eidan FAS; Alrawkan S; Alshammary H; Crowther MA
Ann Hematol; 2018 Nov; 97(11):2055-2059. PubMed ID: 30003318
[TBL] [Abstract][Full Text] [Related]
4. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Lewis BE; Wallis DE; Hursting MJ; Levine RL; Leya F
Chest; 2006 Jun; 129(6):1407-16. PubMed ID: 16778256
[TBL] [Abstract][Full Text] [Related]
5. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis.
Murray PT; Hursting MJ
Ren Fail; 2006; 28(7):537-9. PubMed ID: 17050234
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome.
Mohanty E; Nazir S; Sheppard JI; Forman DA; Warkentin TE
J Thromb Haemost; 2019 May; 17(5):841-844. PubMed ID: 30773806
[TBL] [Abstract][Full Text] [Related]
7. Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy.
Li JF; Wu LJ; Wen GY; Zhou RR; Liu F; Wang W; Yang SQ; Gong JN; Miao R; Gu S; Liu Y; Yang YH
J Thromb Thrombolysis; 2021 Apr; 51(3):703-710. PubMed ID: 32894400
[TBL] [Abstract][Full Text] [Related]
8. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study.
Fisser C; Winkler M; Malfertheiner MV; Philipp A; Foltan M; Lunz D; Zeman F; Maier LS; Lubnow M; Müller T
Crit Care; 2021 Apr; 25(1):160. PubMed ID: 33910609
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review.
Wang Y; Zhang K; Yin L; Fu G; Liu Z
Ann Vasc Surg; 2022 Mar; 80():392.e1-392.e7. PubMed ID: 34656708
[TBL] [Abstract][Full Text] [Related]
10. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
[TBL] [Abstract][Full Text] [Related]
11. Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
Demma LJ; Paciullo CA; Levy JH
J Thorac Cardiovasc Surg; 2012 May; 143(5):1213-8. PubMed ID: 22329977
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after heparin-induced thrombocytopenia in patients with Propaten vascular grafts.
Kasirajan K
Ann Vasc Surg; 2012 Aug; 26(6):802-8. PubMed ID: 22717356
[TBL] [Abstract][Full Text] [Related]
13. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
[TBL] [Abstract][Full Text] [Related]
14. Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients.
Kim YS; Lee H; Yang JH; Sung K; Suh GY; Chung CR; Yang JH; Cho YH
Medicine (Baltimore); 2018 Nov; 97(47):e13235. PubMed ID: 30461625
[TBL] [Abstract][Full Text] [Related]
15. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Bartholomew JR; Hursting MJ
J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of heparin-induced thrombocytopenia in subarachnoid hemorrhage patients: a 4-year, retrospective single-center review.
Benken ST; Tesoro EP; Kim KS; Mucksavage JJ
Neurocrit Care; 2012 Oct; 17(2):177-82. PubMed ID: 22692920
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Hursting MJ; Verme-Gibboney CN
J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
[TBL] [Abstract][Full Text] [Related]
18. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Müller MM; Kropff S; Lindhoff-Last E
J Am Coll Cardiol; 2017 Nov; 70(21):2636-2648. PubMed ID: 29169470
[TBL] [Abstract][Full Text] [Related]
19. A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report.
Lázaro-García A; Martínez-Alfonzo I; Vidal-Laso R; Velasco-Rodríguez D; Tomás-Mallebrera M; González-Rodríguez M; Llamas-Sillero P
Hematology; 2022 Dec; 27(1):318-321. PubMed ID: 35231200
[TBL] [Abstract][Full Text] [Related]
20. How we manage patients with heparin induced thrombocytopenia.
Scully M; Gates C; Neave L
Br J Haematol; 2016 Jul; 174(1):9-15. PubMed ID: 27097741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
